lens intrinsic membrane protein 2Genealiases: CTRCT19 · MP17 · MP19
Q-omics provides the consensus-scored LIM2 profile across patient tissues and cancer cell-line models. LIM2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, LIM2 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, LIM2 RNA expression shows 9,623 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ESCA, KIRC, and TGCT as cancer lineages where LIM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LIM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LIM2 survival associations across molecular data types. LIM2 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LIM2 RNA expression–survival associations across cancer types. High LIM2 expression shows unfavorable associations in SCLC, BRCA and KIRP, but favorable associations in ESCA, CESC and SKCM. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify ESCA as the clearest survival context for LIM2 RNA expression.
This table summarizes LIM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LIM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LIM2 shows lower tumor expression in LUAD, BRCA and LUSC and higher tumor expression in KIRC, HNSC and KICH. The KIRC box plot shows higher LIM2 RNA expression in tumor versus normal tissue (log2 FC = +0.127, t-test p < 0.001).
This table shows molecular features associated with LIM2 in patient tissues and cancer cell lines. In patient samples, LIM2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LIM2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BREAST.
